A drug designed to treat a certain type of cancerous tumor might work well in some patients but not others. To determine why, scientists can study whether specific genetic mutations may impact the therapy’s effectiveness.
Karyopharm Therapeutics, a commercial-stage pharmaceutical company pioneering novel cancer therapies, is taking a closer look at these unique molecular characteristics of different cancers with the help of the Ohio Supercomputer Center (OSC).